Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|#rLOCK|ZpLOCK|X^!%lcR

Johnson & Johnson Earnings: A Steady 2025 and Improving 2026 Warrant a FVE Increase

J&J reported 6% sales growth and 8.1% diluted adjusted EPS growth in 2025, with 2026 growth guidance of 6.7% for sales and 6.9% for diluted adjusted EPS at the midpoint.

Sponsor Center